Episode 4: Innovations in Health Sciences

Chief Investment Officer Tom Herrick and guest Brian Dausch, Vice President and Portfolio Specialist at T. Rowe Price, discuss the innovations in Health Sciences—the pandemic's silver lining.


Brian Dausch, Vice President, Portfolio Specialist, T. Rowe Price

Brian Dausch is a portfolio specialist in the U.S. Equity Division. He is a member of the Global Natural Resources Equity, US Mid-Cap Growth Equity, US Small-Cap Growth Equity, QM US Small-Cap Growth Equity, and Health Sciences Equity Strategy teams, working closely with institutional clients, consultants, and prospects. He is a vice president of T. Rowe Price Group, Inc.  

Brian’s investment experience began in 1997, and he has been with T. Rowe Price since 1998, beginning in the U.S. Equity Division as an associate investment analyst covering biotechnology and pharmaceutical companies. Prior to his current role, Brian managed the U.S. Equity Portfolio Analysis Group.

Brian earned a B.S. in business administration, with a concentration in finance, from the University of Delaware. He also has earned the Chartered Financial Analyst® designation.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Picture of Brian Dausch


Thomas Herrick, Chief Market Strategist, Managing Director, Cary Street Partners

Tom has over 31 years of relevant wealth management experience and has been with Cary Street Partners since 2008. He is responsible for the entire research effort of the firm, leading the team that oversees the asset allocation process for CSP Global Portfolios, the firm’s separately managed account offering.

Tom Herrick Headshot

Explore More Commentary

What does the invasion of Ukraine mean for investors?

Discover our thinking on the implications of current events.

Hear More From Our CIO Conversation Series